@article {You1325, author = {Kai-Yun You and Xin-Hui Zhou and Yan-Hui Jiang and Zhuo-Fei Bi and Yi-Min Liu and Xing-Sheng Qiu}, title = {The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer}, volume = {28}, number = {7}, pages = {1325--1332}, year = {2018}, doi = {10.1097/IGC.0000000000001307}, publisher = {BMJ Specialist Journals}, abstract = {Objectives The optimal interval between surgery and adjuvant treatment has not yet been found in cervical cancer. And whether patients with different FIGO stage should choose different interval is unknown. The purpose of this study was to evaluate whether interval has a different effect on oncologic outcome for patients with different tumor stages.Methods We performed a retrospective study of 226 cervical cancer patients who were treated by surgery and adjuvant therapy from May 2005 to August 2015. All patients were divided into 2 groups according to the interval of 5 weeks. Overall survival (OS) and disease-free survival (DFS) were compared between patients with interval shorter and longer than 5 weeks in the whole group and subgroups. Recurrence patterns were also analyzed. Multivariate analysis was performed to explore clinical factors significantly associated with DFS, local recurrence-free survival and distant metastasis-free survival for patients with stage IB2{\textendash}IIA.Results For patients with stage IA2{\textendash}IB1, the 5-year OS and DFS were similar between groups of short and long interval with also the comparable results of local and distant failure. For patients with IB2{\textendash}IIA, both the OS and DFS in the short-interval group were higher than that in the long-interval group. Besides, the rates of local recurrence were found higher in the group of long interval compared with short interval. Multivariable analysis indicated that time interval was an independent predictor of DFS and local recurrence-free survival for patients with stage IB2{\textendash}IIA.Conclusions In cervical cancer patients, time interval between surgery and adjuvant therapy may have different effects on the prognosis in different FIGO stages.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/28/7/1325}, eprint = {https://ijgc.bmj.com/content/28/7/1325.full.pdf}, journal = {International Journal of Gynecologic Cancer} }